So, we have a nice big window here with regard to picking the dose. So, I would assume that we wanted to start with one dose, get a response there, have the opportunity to modify it if something comes up. But ultimately, we will likely do a small study comparing 6 mg to a lower dose at some future time as we start accumulating the data from the ongoing lori study. Now, with regard to a Phase 3 study for vobra duo and the impact of , we just have to see. Clearly, there has been challenges with regard to getting enough drug into the market. We assume Novartis will improve that over the course of this year and next year. But still, as you know, this is being used mostly very large academic centers and the community physician has less opportunity to treat their patients with .
So, we’ll have to see where things go with regard to the importance of PLUVICTO treatments in the design of the subsequent study.
Boris Peaker: Great. Thanks for taking my questions.
Operator: Thank you. Our next question comes from Charles Zhu with Guggenheim. You may proceed.
Unidentified Analyst: Hi. This is Edward on for Charles Zhu. Thanks for €“ congratulations all the progress. My first question was on the lorigerlimab MGC018 combination study. I’m just curious if you can give any color on how the dose escalation is going? And then any further color on the future data update and what investors could expect there?
Scott Koenig: Thanks, Edward. As I said before, we’re still looking for the right dose combination there that provides both the activity and safety. As we had noted before, we had fixed the dose of the lori and started with a very low dose of vobra duo, but have nothing more to say with regard to identifying the final dose. We’re still in treating patients and looking to see what the appropriate combination would be. With regard to the timing of this, again, we would like to have picked a dose and then move into some expansion cohorts. And it depends on how quickly we will get to select that dose and move into those expansion. There’s an outside shot that maybe later this year more likely in 2024 we’ll have data to discuss.
Unidentified Analyst: Great, thanks. And maybe just as a follow-up question, you’ve got €“ so you’ve got lori and MGC018 and also the combination. I’m just curious how you’re thinking of positioning the or the individual monotherapy and prostate longer-term?
Scott Koenig: Well, I think it all depends on what the €“ both the activity and safety profile is as I pointed out. We want to improve the vobra duo. At this point, we see this in the context of treating prostate cancer to probably more the later line therapy. We look at the opportunity for lori, pretty much across the board from early disease to late disease, but I should point out and one should not forget the fact that the reason why we move forward with molecules targeting B7-H3 and obviously checkpoints as well, is that with regard to B7-H3, most solid tumors expressed B7-H3. So, we see this as an entry point into treating cancer with a great opportunity for the needs of patients with prostate cancer given that even current therapies are not curing patients number one, particularly in later line, and there is no checkpoint that has been approved in prostate cancer.
But ultimately, we look at forward to using both these agents either alone in combination and many other solid tumors as well. And again, depending on how much capital we have available, partnerships going forward, etcetera, will determine how quickly we’re able to expand the use of both drugs.
